The RPS20 antibody is a crucial tool for detecting ribosomal protein S20 (RPS20), a component of the 40S subunit of eukaryotic ribosomes. As part of the small ribosomal subunit, RPS20 plays a vital role in mRNA translation and ribosome biogenesis. Research has linked RPS20 dysregulation to human diseases, including Diamond-Blackfan anemia (DBA), a ribosomopathy characterized by defective erythropoiesis, and certain cancers. For example, germline RPS20 mutations were identified in hereditary colorectal cancer families, suggesting its role in maintaining genomic stability.
RPS20 antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study protein expression, localization, and interactions. These antibodies help elucidate RPS20’s molecular functions, including its involvement in p53-dependent stress responses and ribosome assembly pathways. Commercial RPS20 antibodies are typically raised in hosts like rabbits or mice, targeting specific epitopes with validation in knockout controls. Recent studies also explore RPS20’s potential as a biomarker or therapeutic target, particularly in cancers where its overexpression correlates with tumor progression. However, variability in antibody specificity across experimental conditions necessitates careful validation to ensure reliable results in both basic research and clinical applications.